<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00940251</url>
  </required_header>
  <id_info>
    <org_study_id>MER1</org_study_id>
    <nct_id>NCT00940251</nct_id>
  </id_info>
  <brief_title>Evaluation of Safety and Efficacy of Mersina, an Ayurvedic Formulation: A Double Blind, Placebo Controlled Study in Type 2 Diabetic Patients With Secondary Failure to Oral Drugs</brief_title>
  <official_title>Evaluation of Safety and Efficacy of Mersina, an Ayurvedic Formulation: A Double Blind, Placebo Controlled Study in Type 2 Diabetic Patients With Secondary Failure to Oral Drugs</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jyoti Clinical and Pathological Laboratory</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jyoti Clinical and Pathological Laboratory</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine the safety and efficacy of an Ayurvedic formulation, Mersina in type 2 diabetic
      patients with secondary failure to oral hypoglycemic agents, a randomized double blind,
      single centre, study of 3 months duration was carried out.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2008</start_date>
  <completion_date type="Actual">November 2008</completion_date>
  <primary_completion_date type="Actual">October 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>antidiabetic activity</measure>
    <time_frame>3 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Improvement in metabolic, insulin level, HbA1c,kidney and lipid profile</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">26</enrollment>
  <condition>Antihyperglycemic Effect in Type 2 Diabetic Patients With Secondary Failure to Oral Hypoglycemic Agents</condition>
  <arm_group>
    <arm_group_label>CORN STARCH</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Mersina, Diet and exercise</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mersina</intervention_name>
    <description>capsule, 3g/day, 3 months</description>
    <arm_group_label>CORN STARCH</arm_group_label>
    <arm_group_label>Mersina, Diet and exercise</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Secondary failure to Oral Hypoglycemic Agents was diagnosed if the patient had HbA1c levels
        &gt; 8.5% even after supplementation of maximal dose of a combination of a sulphonylurea (15
        mg glybenclamide or 160 mg gliclazide or 15 mg glipizide) and metformin 1500 mg/day.

        Exclusion Criteria:

        Patients with ketosis, diabetes related complications, hepatic or renal disease,
        pancreatitis, cardiac problems, uncontrolled hypertension, malnutrition and severe immune
        deficiency
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Jyoti Clinical and Pathological Laboratory</name>
      <address>
        <city>Shirpur</city>
        <state>Maharashtra</state>
        <zip>425 405</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>July 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 14, 2009</study_first_submitted>
  <study_first_submitted_qc>July 14, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 15, 2009</study_first_posted>
  <last_update_submitted>July 14, 2009</last_update_submitted>
  <last_update_submitted_qc>July 14, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 15, 2009</last_update_posted>
  <responsible_party>
    <name_title>Jayavant M Jain</name_title>
    <organization>Jyoti Clinical and Pathological Laboratory</organization>
  </responsible_party>
  <keyword>Ayurvedic formulation</keyword>
  <keyword>type 2 diabetes mellitus</keyword>
  <keyword>secondary failure to oral hypoglycemic agents</keyword>
  <keyword>antidiabetic</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasm Metastasis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

